Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ISTODAX | Bristol Myers Squibb | N-022393 RX | 2009-11-05 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
istodax | New Drug Application | 2023-01-31 |
romidepsin | New Drug Application | 2021-12-31 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
t-cell lymphoma peripheral | — | D016411 | — |
t-cell lymphoma cutaneous | — | D016410 | C84.A |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
Triple negative breast neoplasms | D064726 | — | — | 1 | 1 | — | — | — | 1 |
Drug common name | Romidepsin |
INN | romidepsin |
Description | Romidepsin is a cyclodepsipeptide consisting of the cyclic disulfide of (2Z)-2-aminobut-2-enoyl, L-valyl, (3S,4E)-3-hydroxy-7-sulfanylhept-4-enoyl, D-valyl and D-cysteinyl residues coupled in sequence and cyclised head-to tail. It has a role as an antineoplastic agent and an EC 3.5.1.98 (histone deacetylase) inhibitor. It is a cyclodepsipeptide, an organic disulfide and a heterocyclic antibiotic. |
Classification | Protein |
Drug class | depsipeptide derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O |
PDB | — |
CAS-ID | 128517-07-7 |
RxCUI | — |
ChEMBL ID | CHEMBL343448 |
ChEBI ID | 61080 |
PubChem CID | 5352062 |
DrugBank | DB06176 |
UNII ID | CX3T89XQBK (ChemIDplus, GSRS) |